title: LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway.
abstract: LY294002 (LY29) is a commonly used pharmacologic inhibitor of the phosphatidylinositol 3-kinase (PI3K) and has shown antitumorigenic effect both in vivo and in vitro. Both LY29 and its inactive analogue, LY303511 (LY30), significantly up-regulated early growth response gene 1 (Egr-1) expression in HL-60 leukemic cells. However, wortmannin, another commonly used PI3K inhibitor, was not able to induce Egr-1 at the dose that completely blocked Akt phosphorylation. LY29 markedly decreased the invasive cells number through Matrigel and human umbilical vein endothelial cells (HUVECs) compared with the controls. Moreover, the inhibitory effects could be significantly abolished by Egr-1 gene silencing with siRNA technology. Our results indicated for the first time that LY29 could suppress leukemia cell invasion and migration at least in part through up-regulation of Egr-1, independent of its PI3K-Akt inhibitory activity. These data provide a novel explanation for the anticancer properties of LY29 in leukemias.
authors.affiliation: Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, People's Republic of China. liupeng8888@yahoo.com.cn
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Bei
authors.initials: B
authors.lastname: Xu
authors.forename: Jianyong
authors.initials: J
authors.lastname: Li
authors.forename: Hua
authors.initials: H
authors.lastname: Lu
mesh_terms: D002465:Cell Movement / Q000187:drug effects*; D002867:Chromones / Q000494:pharmacology*; D051766:Early Growth Response Protein 1 / Q000235:genetics*; D015870:Gene Expression / Q000187:drug effects*; D018922:HL-60 Cells; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000378:metabolism / Q000473:pathology*; D009025:Morpholines / Q000494:pharmacology*; D009361:Neoplasm Invasiveness; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010879:Piperazines / Q000494:pharmacology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D002867:Chromones; D051766:Early Growth Response Protein 1; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; C093555:LY 303511; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one